Biosimilars: British Columbia extends transition program
By
Aurélia Morvan
|
Oct. 3, 2019, 11:14 a.m.
Photo: Freepik
Rising drug costs are plaguing public and private health insurance plans alike. In response to this trend, British Columbia has extended its program which transitions patients to biosimilar drugs.
This article is reserved to PRO Level subscribers
Discover the PRO Level
Already subscribed? Sign in >
Advertisement
The most popular in Health
Make your business shine with Visibility360!
Get a PDF version to share in your networks.
I'm interestedHeadlines
Advertisement
Related topics …